<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642236</url>
  </required_header>
  <id_info>
    <org_study_id>BTKi in FLT3 mutant AML</org_study_id>
    <nct_id>NCT03642236</nct_id>
  </id_info>
  <brief_title>Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML</brief_title>
  <official_title>Combination of Brutons Tyrosine Kinase (BTK) Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical efficacy of FLT3 inhibitors combining with chemotherapy is usually transient and
      followed by emergence of drug-resistance in FLT3-ITD mutant AML. BTK is reported to be a
      therapeutic target in this subtype leukemia. Our previous study showed inhibition of BTK
      onvercome drug-resistance to FLT3 inhibitors/chemotherapy in refractory/relapsed FLT3 mutant
      AML. In this prospective randomized controlled study, the efficacy and safety of combination
      of BTK inhibitor with chemotherapy with/without FLT3 inhibitor in refractory/relapsed FLT3
      mutant AML are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical efficacy of FLT3 inhibitors combining with chemotherapy is usually transient and
      followed by emergence of drug-resistance in FLT3-ITD mutant acute myeloid leukemia (AML). How
      to overcome the resistance to FLT3 inhibitors or chemotherapy needs further study. Bruton's
      tyrosine kinase (BTK) is reported to be a therapeutic target in this subtype leukemia. Our
      previous study showed inhibition of BTK onvercome drug-resistance to FLT3
      inhibitors/chemotherapy in refractory/relapsed FLT3 mutant AML. In this prospective
      randomized controlled study, we are going to inhibit BTK with BTK inhibitor ibrutinib in the
      patients with refractory/relapsed FLT3 mutant AML, and then test the enhancing effect and
      safety of combination of ibrutinib with chemotherapy with/without FLT3 inhibitor, to make
      sure inhibition of BTK overcomes drug-resistance in FLT3 mutation AML.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>After the first and second cycle induction</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>FLT3-ITD Mutation</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Brutons Tyrosine Kinase</condition>
  <arm_group>
    <arm_group_label>BTK treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTK-free treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.</description>
    <arm_group_label>BTK treatment</arm_group_label>
    <arm_group_label>BTK-free treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Refractoty/relapsed FLT3-ITD mutation AML Age 14-60

        Exclusion Criteria:

        Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
        Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guopan Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>yuguopan</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

